ImmunisBio and Preclina Sign MOU to Cooperate on New Drug Development for Cell Therapy Commercialization

ImmunisBio, a cell therapy developer, announced on July 17 that it has signed a memorandum of understanding (MOU) with Preclina, a preclinical platform company specializing in humanized mouse models, to strengthen cooperation for the development and commercialization of new cell therapy drugs.

The goal is to establish a strong partnership throughout the entire development cycle of cell therapies to overcome intractable diseases by leveraging core technology synergies.

ImmunisBio is conducting clinical trials for gastric cancer, breast cancer, and peritoneal metastatic gastrointestinal cancer based on its immune cell therapy platform. The company is also expanding into the field of advanced regenerative medicine targeting intractable diseases. ImmunisBio is enhancing its commercial capabilities in areas such as cell therapy CDMO, automated cell therapy production, quality analysis services, cell culture media, and cell-based cosmetics, thereby securing its market competitiveness.

Preclina provides preclinical efficacy evaluation services for a wide range of disease groups, including autoimmune, inflammatory, and anti-cancer immunity, through its proprietary humanized mouse platform, the PreHu™ series. The company has demonstrated the potential of alternative testing methods by commercializing the world’s first humanized pulmonary fibrosis (BILF) model. Recently, Preclina established a North American subsidiary in Boston, USA, accelerating its global business expansion.

Through this agreement, the two companies plan to collaborate in various areas by utilizing humanized mice based on immunomodulation technology, including: verification of cell therapy efficacy, exploration of new indications, and establishment of companion diagnostic strategies.

Kang Junghwa, CEO of ImmunisBio, stated, “We are successfully conducting preclinical studies of Treg cell therapy for the Ministry of SMEs and Startups’ strategic technology theme project (DCP), which was selected last year, in collaboration with Preclina. Through this business agreement, we expect to comprehensively strengthen clinical access strategies for cell therapies and create synergy in expanding new indications.”

In addition to clinical trials, the two companies have agreed to closely cooperate in building a network for the successful commercialization and distribution of ImmunisBio’s immune cell therapy ‘MYJ1633,’ which is being prepared for entry into the Central Asian and European markets.